Tourmaline Bio (TRML) Competitors

Vera Therapeutics (NASDAQ:VERA) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, community ranking, valuation, risk and institutional ownership.

Is VERA or TRML more profitable?

Tourmaline Bio's return on equity of -20.97% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-50.13%	-39.50%
Tourmaline Bio	N/A	-20.97%	-20.56%

Do analysts recommend VERA or TRML?

Vera Therapeutics presently has a consensus price target of $64.67, suggesting a potential upside of 139.95%. Tourmaline Bio has a consensus price target of $45.20, suggesting a potential upside of 164.02%. Given Tourmaline Bio's higher possible upside, analysts plainly believe Tourmaline Bio is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.20
Tourmaline Bio	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor VERA or TRML?

In the previous week, Vera Therapeutics had 1 more articles in the media than Tourmaline Bio. MarketBeat recorded 3 mentions for Vera Therapeutics and 2 mentions for Tourmaline Bio. Vera Therapeutics' average media sentiment score of 1.74 beat Tourmaline Bio's score of 0.00 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tourmaline Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, VERA or TRML?

Vera Therapeutics has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.35, indicating that its share price is 135% more volatile than the S&P 500.

Does the MarketBeat Community favor VERA or TRML?

Vera Therapeutics received 20 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 66.13% of users gave Vera Therapeutics an outperform vote.

Company	Underperform	Outperform
Vera Therapeutics	Outperform Votes 41 66.13%	Underperform Votes 21 33.87%
Tourmaline Bio	Outperform Votes 21 100.00%	Underperform Votes No Votes

Do institutionals & insiders hold more shares of VERA or TRML?

99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are owned by institutional investors. 21.7% of Vera Therapeutics shares are owned by company insiders. Comparatively, 11.0% of Tourmaline Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has preferable valuation and earnings, VERA or TRML?

Vera Therapeutics is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$95.99M	-$2.75	-9.80
Tourmaline Bio	N/A	N/A	-$42.12M	-$2.87	-5.97

Summary

Vera Therapeutics beats Tourmaline Bio on 8 of the 15 factors compared between the two stocks.